Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS.

Authors: Joan Carles, Bertrand F. Tombal, Maha H. A. Hussain, Fred Saad, Karim Fizazi, Alvaro Montesa Pino, Maria Jose' Méndez-Vidal, Alejo Rodriguez-Vida, Daniel Castellano, Pablo Borrega, Patrick Adorjan, Cristina Moretones, Manjari Dissanayake, Matthew R Smith

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.143

Source: Full article

---

Abstract

143